Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX)
Recursion Pharmaceuticals, Inc. Class A (RXRX) is a biotechnology company that leverages machine learning and automation to discover and develop new medicines. Founded with a focus on using data-driven approaches to accelerate drug discovery, Recursion combines high-throughput biology, AI, and computational science to identify potential therapeutic candidates across various diseases. The company aims to streamline the development process and improve success rates in bringing innovative treatments to market.
Company News
Christopher Gibson, CEO of Recursion Pharmaceuticals, sold 100,000 shares worth approximately $604,000, representing about 9.49% of his direct holdings. The transaction reflects ongoing stock sales and potential challenges in the company's drug development strategy.
Absci Corp, a small AI biotech company, offers high-risk investment potential in drug discovery using generative AI, with multiple drug candidates in clinical trials and strategic partnerships with major pharma companies.
The global drug discovery platforms market is projected to grow from $186.24 million in 2024 to $635.45 million by 2034, driven by AI, technological advancements, and increased pharmaceutical R&D investments. North America leads the market, with Asia-Pacific expected to see the fastest growth.
Rallybio Corporation sold its interest in REV102, a preclinical ENPP1 inhibitor for hypophosphatasia, to Recursion Pharmaceuticals for up to $25 million, extending its cash runway into mid-2027.
Recursion Pharmaceuticals (RXRX) reachead $9.38 at the closing of the latest trading day, reflecting a +0.43% change compared to its last close.